StockMirror — Stock Screener

AARTIDRUGS Q2 FY27 Results & Earnings Analysis

Sentiment: Great (Confidence: high)

Earnings Summary

Aarti Drugs reported a milestone Q2 FY27 with record consolidated revenue of Rs. 829 crores (up 27% YoY), highest-ever EBITDA of Rs. 138 crores (up 63% YoY), and PAT of Rs. 83 crores (up 83% YoY). EBITDA margin expanded 370 bps YoY to 16.6%, and PAT margin expanded 310 bps to 10.0%. Growth was driven by 17-18% price realization improvement, 5% volume growth, and exceptional formulation exports (up 58% YoY). Management expects to sustain ~15% EBITDA margins with volume growth of 5-10% for FY27. Capacity expansions at Tarapur, Sarigam, and Baddi are underway to support future growth, with formulation business targeting Rs. 1,000 crores earlier than planned. Key risks include volume deferrals due to high prices and potential normalization of exceptional formulation margins.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized growing volumes, improving product mix, and lowering costs through backward integration and process improvement. Targeting 5-10% volume growth while sustaining ~15% EBITDA margins with potential upside.

About Aarti Drugs Limited

Aarti Drugs Limited (AARTIDRUGS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More